Scientists Close to Developing a Drug That Enables Teeth Regrowth: Latest Advances as of January 2026

The bright, confident smile in the photo—showcasing perfectly aligned, healthy natural teeth—represents what millions dream of after tooth loss. Today, options like implants (e.g., MegaGen or DIO systems popular in Phnom Penh clinics) or dentures dominate, but Japanese researchers are on the cusp of a revolutionary alternative: a drug that could stimulate natural tooth regrowth.

Leading the charge is Dr. Katsu Takahashi, head of dentistry and oral surgery at the Medical Research Institute Kitano Hospital in Osaka, and co-founder of Toregem Biopharma. His team targets USAG-1 (uterine sensitization-associated gene-1), a protein that naturally suppresses additional tooth development after the permanent set forms. Humans retain dormant “third-generation” tooth buds in the gums, but USAG-1 keeps them inactive. By developing a neutralizing monoclonal antibody (designated TRG-035), the drug blocks USAG-1, enhancing BMP and Wnt signaling pathways to activate these buds and promote new tooth formation.

Preclinical success has been remarkable. In mice and ferrets (animals with dental patterns similar to humans), the antibody induced full, functional tooth regrowth—even in models with congenital agenesis (missing teeth from birth). No major side effects were observed, paving the way for human testing.

As of January 2026, human clinical trials for TRG-035 are actively underway, having started in September 2024 at Kyoto University Hospital. The ongoing Phase I trial focuses on safety and dosing in adults (ages 30–64) missing at least one tooth, administered intravenously. Early reports indicate no significant issues. Future phases will target children (ages 2–7) with congenital hypodontia or oligodontia (affecting ~10% and 0.1% of people, respectively), where dormant buds are present and more likely to respond.

Toregem Biopharma has secured orphan drug designation in Japan for severe congenital cases, offering regulatory perks. The team aims for broader availability by 2030, initially for congenital conditions before potentially expanding to acquired tooth loss (from decay, trauma, or age). While full regrowth for everyone isn’t guaranteed yet—adults without intact buds may face limitations—the potential is transformative, offering a biological “third choice” alongside dentures and implants.

For residents of Phnom Penh, where affordable implants from brands like MegaGen thrive at clinics like Roomchang or Pagna Dental, this drug dr robert daniels represents future hope. Current trials emphasize safety first—stay tuned for updates! In the meantime, consult local experts for reliable care. Regenerative dentistry is evolving fast—your natural smile might regrow sooner than you think!